PharmaEngine, Inc. (TPEX:4162)

Market Cap	11.35B
Revenue (ttm)	2.55B
Net Income (ttm)	1.77B
Shares Out	143.68M
EPS (ttm)	12.31
PE Ratio	6.42
Forward PE	n/a
Dividend	6.00 (7.55%)
Ex-Dividend Date	Aug 12, 2024

Volume	464,332
Average Volume	574,186
Open	79.50
Previous Close	79.50
Day's Range	78.60 - 79.70
52-Week Range	74.80 - 123.00
Beta	0.26
RSI	30.41
Earnings Date	Jul 29, 2025

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 44
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2024, PharmaEngine's revenue was 2.52 billion, an increase of 228.70% compared to the previous year's 767.67 million. Earnings were 1.75 billion, an increase of 537.55%.